Company Performance Metrics
Roland Gamp: Head of Finance- Roland Fabis: Head of Operations
Cube Biotech offers innovative products and solutions for membrane protein research – a hotspot for pharmaceutical research. The business model is a two pillared model based on a service business unit that has the potential to generate significant milestone payments and a product business that is securing a constant revenue stream.
The major focus
of Cube’s service business unit is the structural analysis of membrane proteins – a highly sought after discipline. Those play a crucial role in the aetiology of various diseases and are one of the most sought after targets in drug discovery.
Structural analysis of membrane proteins is still a huge challenge. This is particularly true for pharmaceutically relevant human membrane proteins, e.g. transporters or G-protein coupled receptors (GPCRs). The design of efficient drugs depends on the availability of membrane protein structure information.
The competitive advantage of Cube is the coverage of the full value chain in membrane protein research through both value adding products and services based on an unique technology. With this portfolio Cube offers unseen opportunities in membrane protein research for customers in the pharmaceutical and biotechnological industry and aca-demia. The relevance of the scientific arena Cube is operating in was recently confirmed with the award of the 2012’s Nobel Prize in chemistry for two US-scientists for their membrane protein research.
The Cube Biotech team shares more than 40 years of experience on membrane protein expression, purification, and crystallization.
